Eledon reports 24-month Phase 2 BESTOW extension data showing higher eGFR with tegoprubart vs tacrolimus in kidney transplant patients
ELDN•BESTOW extension data and development update
- Eledon disclosed updated long-term Phase 2 BESTOW extension results, already presented at The Transplantation Society meeting in Sydney.
- Tegoprubart patients showed better sustained kidney graft function than tacrolimus, supporting a potential shift away from calcineurin-based regimens.
- Rejection events stopped after the early post-transplant period in the tegoprubart arm, while the tacrolimus arm recorded additional cases.
- FDA granted Fast Track designation for tegoprubart in kidney transplant rejection prevention, strengthening the regulatory path toward late-stage development.
- A global Phase 3 LEGACY trial is slated to start in Q4 2026, targeting about 600 patients with a 12-month composite efficacy endpoint.
